{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:10:14Z","timestamp":1761822614349,"version":"3.43.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1023\/a:1026144518686","type":"journal-article","created":{"date-parts":[[2003,11,3]],"date-time":"2003-11-03T17:50:32Z","timestamp":1067881832000},"page":"47-57","source":"Crossref","is-referenced-by-count":7,"title":["Clinician Update: Direct Thrombin Inhibitors in Acute Coronary Syndromes"],"prefix":"10.1007","volume":"15","author":[{"given":"Joanna J.","family":"Wykrzykowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sekar","family":"Kathiresan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ik-Kyung","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5146233_CR1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/01.CIR.77.3.526","volume":"77","author":"K Gotoh","year":"1988","unstructured":"Gotoh K, Minamino T, Katoh O, et al. The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks. Circulation 1988;77:526-534.","journal-title":"Circulation"},{"key":"5146233_CR2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.CIR.92.3.657","volume":"92","author":"E Falk","year":"1995","unstructured":"Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-671.","journal-title":"Circulation"},{"key":"5146233_CR3","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.90.4.2126","volume":"90","author":"V Fuster","year":"1994","unstructured":"Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90:2126-2146.","journal-title":"Circulation"},{"key":"5146233_CR4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","volume":"319","author":"P Theroux","year":"1994","unstructured":"Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Eng J Med 1994;319:1105-1111.","journal-title":"N Eng J Med"},{"key":"5146233_CR5","doi-asserted-by":"crossref","first-page":"20959","DOI":"10.1074\/jbc.M010584200","volume":"276","author":"PC Liaw","year":"2001","unstructured":"Liaw PC, Becker DL, Stafford AR, et al. Molecular basis for the susceptibility of fibrin-bound thrombin inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 2001;276:20959-20965.","journal-title":"J Biol Chem"},{"key":"5146233_CR6","doi-asserted-by":"crossref","first-page":"258S","DOI":"10.1378\/chest.108.4_Supplement.258S","volume":"108","author":"J Hirsh","year":"1995","unstructured":"Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258S- 275S.","journal-title":"Chest"},{"key":"5146233_CR7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","volume":"335","author":"GUSTO IIb Investigators.","year":"1996","unstructured":"GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Eng J Med 1996; 335: 775-782.","journal-title":"N Eng J Med"},{"key":"5146233_CR8","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood.V96.5.1703","volume":"96","author":"TE Warkentin","year":"2000","unstructured":"Warkentin TE, Sheppard JI, Horsewood P, et al. Impact of patient population on the risk of heparin-induced thrombocytopenia. Blood 2000;96:1703-1708.","journal-title":"Blood"},{"key":"5146233_CR9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-0038-1648875","volume":"72","author":"CN Berry","year":"1994","unstructured":"Berry CN, Girardot C, Lecoffre C, et al. Effects of synthetic thrombin inhibitor argatroban on fibrin-or clotincorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381-386.","journal-title":"Thromb Haemost"},{"key":"5146233_CR10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-2007-999007","volume":"22","author":"RB Wallis","year":"1996","unstructured":"Wallis RB. Hirudins: from leeches to man. Semin Thromb Hemost 1996;22:185-196.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"5146233_CR11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1015368126304","volume":"13","author":"S Kathiresan","year":"2002","unstructured":"Kathiresan S, Shiomura J, Jang IK. Argatroban. J Thrombosis and Thrombolysis 2002;13(1):41-47.","journal-title":"J Thrombosis and Thrombolysis"},{"key":"5146233_CR12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","volume":"94","author":"Antman EM for the TIMI 9B Investigators.","year":"1996","unstructured":"Antman EM for the TIMI 9B Investigators. Hirudin in acute myocardial infarction. Circulation 1996;94:911-921.","journal-title":"Circulation"},{"key":"5146233_CR13","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/01.CIR.89.4.1545","volume":"89","author":"The TIMI IIIB Investigators.","year":"1994","unstructured":"The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction. Circulation 1994;89:1545- 1556.","journal-title":"Circulation"},{"key":"5146233_CR14","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/0735-1097(94)90581-9","volume":"23","author":"CP Cannon","year":"1994","unstructured":"Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue type plasminogen activator and aspirin in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993-1003.","journal-title":"J Am Coll Cardiol"},{"key":"5146233_CR15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0002-9149(99)80517-7","volume":"75","author":"LV Lee","year":"1995","unstructured":"Lee LV. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of TIMI 6 trial. Am J Cardiol 1995;75:7-13.","journal-title":"Am J Cardiol"},{"key":"5146233_CR16","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/01.CIR.90.4.1631","volume":"90","author":"GUSTO IIa Investigators.","year":"1994","unstructured":"GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637.","journal-title":"Circulation"},{"key":"5146233_CR17","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/01.CIR.90.4.1624","volume":"90","author":"Antman EM for the TIMI 9A Investigators.","year":"1994","unstructured":"Antman EM for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the TIMI 9A trial. Circulation 1994;90:1624-1630.","journal-title":"Circulation"},{"key":"5146233_CR18","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1161\/01.CIR.90.4.1638","volume":"90","author":"KL Neuhaus","year":"1994","unstructured":"Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. Circulation 1994; 90: 1638-1642.","journal-title":"Circulation"},{"issue":"4","key":"5146233_CR19","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0735-1097(99)00319-8","volume":"34","author":"KL Neuhaus","year":"1999","unstructured":"Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. J Am Coll Cardiol 1999;34(4):966-973.","journal-title":"J Am Coll Cardiol"},{"key":"5146233_CR20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(98)07332-2","volume":"353","author":"OASIS-2 Investigators.","year":"1999","unstructured":"OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: randomized trial. Lancet 1999;353:429-438.","journal-title":"Lancet"},{"key":"5146233_CR21","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1161\/01.CIR.103.18.2310","volume":"103","author":"EA Antman","year":"2001","unstructured":"Antman EA The search for replacement for unfractionated heparin. Circulation 2001;103:2310-2314.","journal-title":"Circulation"},{"key":"5146233_CR22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/01.CIR.96.3.769","volume":"96","author":"Organization to Assess Strategies for Ischemic Syndromes","year":"1997","unstructured":"Organization to Assess Strategies for Ischemic Syndromes (OASIS). Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation 1997;96:769-777.","journal-title":"Circulation"},{"key":"5146233_CR23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199509213331203","volume":"333","author":"PW Serruys","year":"1995","unstructured":"Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. HELVETICA Investigators. N Eng J Med 1995;333:757-763.","journal-title":"N Eng J Med"},{"issue":"7","key":"5146233_CR24","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/0735-1097(95)00371-1","volume":"26","author":"HJ Rupprecht","year":"1995","unstructured":"Rupprecht HJ, Terres W, Ozbek C, et al. Recombinant hirudin (HBW023) prevents troponin T release after coronary angioplasty in patients with unstable angina. J Am Coll Cardiol 1995;26(7):1637-1642.","journal-title":"J Am Coll Cardiol"},{"key":"5146233_CR25","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1161\/01.CIR.89.4.1567","volume":"89","author":"RM Lindon","year":"1994","unstructured":"Lindon RM, Theroux P, Lesperance J, et al. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994;89:1567-1572.","journal-title":"Circulation"},{"key":"5146233_CR26","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.CIR.91.8.2132","volume":"91","author":"P Theroux","year":"1995","unstructured":"Theroux P, Perez-Villa F, Waters D, et al. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995;91:2132-2139.","journal-title":"Circulation"},{"key":"5146233_CR27","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.CIR.96.7.2155","volume":"96","author":"HD White","year":"1997","unstructured":"White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155- 2161.","journal-title":"Circulation"},{"issue":"9296","key":"5146233_CR28","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(01)06887-8","volume":"358","author":"HD White","year":"2001","unstructured":"White HD and the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358(9296):1855- 1863.","journal-title":"Lancet"},{"key":"5146233_CR29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/01.CIR.92.4.727","volume":"92","author":"J Fuchs","year":"1995","unstructured":"Fuchs J, Cannon CP, for TIMI7 Investigators. Hirulog in the treatment of unstable angina. Results of the TIMI 7 trial. Circulation 1995;92:727-733.","journal-title":"Circulation"},{"key":"5146233_CR30","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","volume":"333","author":"JA Bittl","year":"1995","unstructured":"Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Eng J Med 1995;333:764-769.","journal-title":"N Eng J Med"},{"issue":"6","key":"5146233_CR31","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mhj.2001.119374","volume":"142","author":"JA Bittl","year":"1001","unstructured":"Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 1001;142(6):952-990.","journal-title":"Am Heart J"},{"issue":"5","key":"5146233_CR32","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1067\/mhj.2002.122173","volume":"143","author":"AM Lincoff","year":"2002","unstructured":"Lincoff AM, Kleiman NS, Meierson ES, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002;143(5):847-853.","journal-title":"Am Heart J"},{"issue":"7","key":"5146233_CR33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","volume":"289","author":"AM Lincoff","year":"2003","unstructured":"Lincoff AM, Bittle JA, Harrington RA, et al. for the REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention. JAMA 2003; 289(7):853-863.","journal-title":"JAMA"},{"key":"5146233_CR34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","volume":"352","author":"The EPISTENT Inverstigators.","year":"1998","unstructured":"The EPISTENT Inverstigators. Randomised placebocontrolled and baloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade. Lancet 1998;352:87-92.","journal-title":"Lancet"},{"key":"5146233_CR35","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","volume":"356","author":"The ESPRIT Investigators.","year":"2000","unstructured":"The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-2044.","journal-title":"Lancet"},{"key":"5146233_CR36","first-page":"1880","volume":"33","author":"IK Jang","year":"1999","unstructured":"Jang IK, Brown DF, Giugliano RP, et al. A multicenter randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (tPA) in acute myocardial infarction: myocardial infarction with novastan and tPA (MINT) study. J Am Coll Cardiol 1999;33:1880-1885.","journal-title":"J Am Coll Cardiol"},{"key":"5146233_CR37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1023\/A:1026591023462","volume":"10","author":"F Vermeer","year":"2000","unstructured":"Vermeer F, Vahanian A, Fels PW, et al. Argatroban and anteplase in patients with acute myocardial infarction: the ARGAMI study. J Thromb and Throbolysis 2000;10:233-240.","journal-title":"J Thromb and Throbolysis"},{"issue":"Suppl1","key":"5146233_CR38","first-page":"1453","volume":"98","author":"S Behar","year":"1998","unstructured":"Behar S, Hod H, Kaplinsky E, for the ARGAMI-2 Study Group. Argatroban versus heparin as adjuvant therapy to thrombolysis for acute myocardial infarction: safety considerations\u2013ARGAMI-2 study. Circulation 1998;98(Suppl 1):1453-1454.","journal-title":"Circulation"},{"key":"5146233_CR39","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0735-1097(93)90222-M","volume":"21","author":"HK Gold","year":"1993","unstructured":"Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993;21:1039-1047.","journal-title":"J Am Coll Cardiol"},{"key":"5146233_CR40","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","volume":"103","author":"BE Lewis","year":"2001","unstructured":"Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparininduced thrombocytopenia. Circulation 2001;103:1838- 1843.","journal-title":"Circulation"},{"key":"5146233_CR41","doi-asserted-by":"crossref","unstructured":"Jang IK, Lewis BE, Matthai WH, et al. Combination of a direct thrombin inhibitor, Argatroban and glycoprotein IIb\/IIIa inhibitor is effective and safe in patients undergoing percutaneous coronary intervention. ACC 2002 (submitted abstract)","DOI":"10.1016\/S0735-1097(03)80906-3"},{"key":"5146233_CR42","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/01.CIR.94.7.1719","volume":"94","author":"TJ Shetler","year":"1996","unstructured":"Shetler TJ, Crowe VG, Bailey BD, et al. Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis. Circulation 1996;94:1719-1725.","journal-title":"Circulation"},{"key":"5146233_CR43","doi-asserted-by":"crossref","unstructured":"Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: the Promotion of reperfusion in Myocardial Infarction Evolution (PRIME) trial. Am Heart J 2002:143(1):95-105.","DOI":"10.1067\/mhj.2002.119896"},{"issue":"4","key":"5146233_CR44","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0002-8703(99)70185-7","volume":"138","author":"AY Fung","year":"1999","unstructured":"Fung AY, Lorch G, Cambier PA, et al. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators. Am Heart J 1999;138(4 pt 1):696-704.","journal-title":"Am Heart J"},{"issue":"15","key":"5146233_CR45","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1053\/euhj.1999.1477","volume":"20","author":"P Klootwijk","year":"1999","unstructured":"Klootwijk P, Lenderink T, Meij S, et al. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J 1999;20(15):1101-1111.","journal-title":"Eur Heart J"},{"key":"5146233_CR46","doi-asserted-by":"crossref","unstructured":"Jang IK Direct thrombin Inhibitors in acute coronary syndromes. Lancet 2002;360(9331):491-492 (Correspondence).","DOI":"10.1016\/S0140-6736(02)09656-3"},{"key":"5146233_CR47","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(02)07495-0","volume":"359","author":"Direct thrombin inhibitor trialists' collaborative group","year":"2002","unstructured":"Direct thrombin inhibitor trialists' collaborative group.Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002;359:294-302.","journal-title":"Lancet"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1026144518686.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1026144518686\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1026144518686.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T07:23:11Z","timestamp":1754637791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1026144518686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["5146233"],"URL":"https:\/\/doi.org\/10.1023\/a:1026144518686","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"type":"print","value":"0929-5305"},{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}